Nombre del producto:Bromonitromethane

IUPAC Name:bromo(nitro)methane

CAS:563-70-2
Fórmula molecular:CH2BrNO2
Pureza:95%+
Número de catálogo:CM422771
Peso molecular:139.94

Unidad de embalaje Stock disponible Precio($) Cantidad
CM422771-50g in stock ijǟǟǟ
CM422771-100g in stock ijƈƈƈ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :563-70-2
Fórmula molecular:CH2BrNO2
Punto de fusión:-
Código de sonrisas:[O-][N+](=O)CBr
Densidad:
Número de catálogo:CM422771
Peso molecular:139.94
Punto de ebullición:
Nº Mdl:MFCD00007401
Almacenamiento:

Column Infos

Nanatinostat
Epstein–Barr virus (EBV) has been associated with malignant lymphomas of B-cell, T-cell, and NK-cell origin. EBV infection of lymphoma cells leads to the development of cancers with an unmet medical need. The innovative ‘Kick and Kill’ approach targets EBV with Nanatinostat and Valganciclovir, in which Nanatinostat activates Ganciclovir by inducing the expression of EBV kinase genes. Ganciclovir then converts to cytotoxic form and results in apoptosis
Histone deacetylase (HDAC) is involved in the regulation of gene expression. HDAC inhibition induces cell cycle arrest and reactivates normal expression of tumor cells. Nanatinostat is such a potent hydroxamic acid-based class I-selective HDAC inhibitor. Nanatinostat is being studied with the antiviral agent Valganciclovir in EBV-associated malignancies. Viracta Therapeutics recently reports positive topline Nana-val results from stage 1 of the NAVAL-1 Trial from both arms of the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) peripheral T-cell lymphoma (PTCL) cohort.